Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.60 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18231973 | 0.85 | HTT (0.72) | HTTNR2F2PDE5AHRH4PIK3CD | |
| SCHEMBL29199913 | 0.83 | ALK (0.58) | HTTDYRK1AMEN1MAPTKMT2A | |
| SCHEMBL30827833 | 0.83 | ALK (0.58) | HTTDYRK1AMEN1MAPTKMT2A | |
| SCHEMBL30827907 | 0.81 | HTT (0.58) | HTTNR2F2PIK3CDPIK3R1CLK4 | |
| SCHEMBL23202834 | 0.81 | HTT (0.58) | HTTNR2F2PIK3CDPIK3R1CLK4 | |
| SCHEMBL23202948 | 0.81 | HRH4 (0.48) | HTTPDE5AHRH4CNR1MEN1 | |
| SCHEMBL30827810 | 0.81 | HRH4 (0.48) | HTTPDE5AHRH4CNR1MEN1 | |
| SCHEMBL23202858 | 0.80 | HTT (0.69) | HTTNR2F2PDE5AMAPK1MEN1 | |
| SCHEMBL28502337 | 0.79 | DYRK1A (0.49) | NR2F2CNR1CNR2DYRK1ALMNA | |
| SCHEMBL23202908 | 0.79 | HTT (0.69) | HTTNR2F2PDE5AHRH4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | claimed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | claimed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | claimed |
| EP-3802495-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-14 | — | — | EP | claimed |
| CN-112204010-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | claimed |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | disclosed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3802495-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-14 | — | — | EP | disclosed |
| CN-112204010-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, IRF3 | HTT 1901/4885NR2F2 1890/4885PDE5A 2387/4885 |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, IRF3 | HTT 1901/4885NR2F2 1890/4885PDE5A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.